PMID- 34805180
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211123
IS  - 2296-634X (Print)
IS  - 2296-634X (Electronic)
IS  - 2296-634X (Linking)
VI  - 9
DP  - 2021
TI  - A Novel Prognostic Model Based on the Serum Iron Level for Patients With 
      Early-Stage Triple-Negative Breast Cancer.
PG  - 777215
LID - 10.3389/fcell.2021.777215 [doi]
LID - 777215
AB  - The dysregulation of iron homeostasis has been explored in malignancies. However, 
      studies focusing on the association between the serum iron level and prognosis of 
      patients with early-stage triple-negative breast cancer (TNBC) are scarce. 
      Accordingly, in current study, 272 patients with early-stage TNBC treated at Sun 
      Yat-sen University Cancer Center (SYSUCC) between September 2005 and October 2016 
      were included as a training cohort, another 86 patients from a previous 
      randomized trial, SYSUCC-001, were analyzed as a validation cohort (SYSUCC-001 
      cohort). We retrospectively collected their clinicopathological data and tested 
      the serum iron level using blood samples at the diagnosis. In the training 
      cohort, patients were divided into low-iron and high-iron groups according to the 
      serum iron level cut-off of 17.84 mumol/L determined by maximally selected rank 
      statistics. After a median follow-up of 87.10 months, patients with a low iron 
      had a significantly longer median disease-free survival (DFS) of 89.13 
      [interquartile range (IQR): 66.88-117.38] months and median overall survival (OS) 
      of 92.85 (IQR: 68.83-117.38) months than those in the high-iron group (median 
      DFS: 75.25, IQR: 39.76-105.70 months, P = 0.015; median OS: 77.17, IQR: 
      59.38-110.28 months, P = 0.015). Univariate and multivariate Cox analysis 
      demonstrated the serum iron level to be an independent predictor for DFS and OS. 
      Then, a prognostic nomogram incorporating the serum iron level, T stage and N 
      stage was developed for individualized prognosis predictions. It had good 
      discriminative ability with a C-index of DFS (0.729; 95% CI 0.666-0.792) and OS 
      (0.739; 95% CI 0.666-0.812), respectively. Furtherly, we validated the predictive 
      model in the SYSUCC-001 cohort, which also showed excellent predictive 
      performance with a C-index of DFS (0.735; 95% CI 0.614-0.855) and OS (0.722; 95% 
      CI 0.577-0.867), respectively. All these suggested that the serum iron level 
      might be a potential prognostic biomarker for patients with early-stage TNBC, the 
      predictive model based on it might be served as a practical tool for 
      individualized survival predictions.
CI  - Copyright (c) 2021 Hua, Duan, Huang, Bi, Xia, Song, Wang, Jiang and Yuan.
FAU - Hua, Xin
AU  - Hua X
AD  - Department of Medical Oncology, The State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Duan, Fangfang
AU  - Duan F
AD  - Department of Medical Oncology, The State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Huang, Jiajia
AU  - Huang J
AD  - Department of Medical Oncology, The State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Bi, Xiwen
AU  - Bi X
AD  - Department of Medical Oncology, The State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Xia, Wen
AU  - Xia W
AD  - Department of Medical Oncology, The State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Song, Chenge
AU  - Song C
AD  - Department of Medical Oncology, The State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Wang, Li
AU  - Wang L
AD  - Department of Medical Oncology, The State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Jiang, Chang
AU  - Jiang C
AD  - Department of Medical Oncology, The State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Yuan, Zhongyu
AU  - Yuan Z
AD  - Department of Medical Oncology, The State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20211104
PL  - Switzerland
TA  - Front Cell Dev Biol
JT  - Frontiers in cell and developmental biology
JID - 101630250
PMC - PMC8599954
OTO - NOTNLM
OT  - early-stage triple-negative breast cancer
OT  - nomogram
OT  - predictive model
OT  - serum iron level
OT  - survival
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/11/23 06:00
MHDA- 2021/11/23 06:01
PMCR- 2021/01/01
CRDT- 2021/11/22 06:53
PHST- 2021/09/15 00:00 [received]
PHST- 2021/10/11 00:00 [accepted]
PHST- 2021/11/22 06:53 [entrez]
PHST- 2021/11/23 06:00 [pubmed]
PHST- 2021/11/23 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fcell.2021.777215 [doi]
PST - epublish
SO  - Front Cell Dev Biol. 2021 Nov 4;9:777215. doi: 10.3389/fcell.2021.777215. 
      eCollection 2021.